New Delhi: There are now clear experimental and clinical data that supports very high immune runaway potential from Omicron, but the initial estimate shows the severity of a lower disease than what is seen in the previous outbreak, the consortium of SARS-COV-2 Incacog genomics in the latest bulletin Citing global data.
In India, the right public health measures and investigations are being carried out for Omicron supervision, Insacog said while noting that globally seems to significantly reduce the ability of vaccines or previous infections to protect from the infection of symptoms by the omicron variant.
“While Delta continues to be the most common VOC globally, Omicron variants actually move it to South Africa and are on track to become the dominant variant in the UK and elsewhere,” Insacog said in the bulletin released on Wednesday.
The genome consortium, citing global data, said there are now clear experimental and clinical data that supports the very high potential for immune runaway from Omicron, which seems to be the main component of its growth excellence on Delta.
“The initial estimate of the severity of the disease, however, is lower than the previous outbreak.
Is this initial observation generalized for older non-immune subjects and the threat level is still considered high,” he said.
Insacog reports the supervision of the Genome SARS COV -2 throughout the country through sample sequencing from Sentinel sites and also detailed regency analysis of countries for several countries.
India has recorded 781 cases of omicron coronavirus variants in 21 states and UTS so far, where 241 people have recovered or migrated, according to data on the Ministry of Health Union updated on Wednesday.